Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C. , Ozguroglu M. , ...More

ANNALS OF ONCOLOGY, vol.31, no.6, pp.798-806, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1016/j.annonc.2020.03.287
  • Title of Journal : ANNALS OF ONCOLOGY
  • Page Numbers: pp.798-806
  • Keywords: durvalumab, immunotherapy, non-small-cell lung cancer, PACIFIC, PD-L1 expression, stage III, DEATH-LIGAND 1, INHIBITORS, NSCLC


Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression.